Premium
Cytoprotective Encapsulation of Individual Jurkat T Cells within Durable TiO 2 Shells for T‐Cell Therapy
Author(s) -
Youn Wongu,
Ko Eun Hyea,
Kim MiHee,
Park Matthew,
Hong Daewha,
Seisenbaeva Gulaim A.,
Kessler Vadim G.,
Choi Insung S.
Publication year - 2017
Publication title -
angewandte chemie international edition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.831
H-Index - 550
eISSN - 1521-3773
pISSN - 1433-7851
DOI - 10.1002/anie.201703886
Subject(s) - jurkat cells , cell therapy , adoptive cell transfer , cancer immunotherapy , cell , microbiology and biotechnology , immunotherapy , t cell , lymphocyte , cytotoxic t cell , in vitro , immunology , immune system , cancer research , chemistry , biology , biochemistry
Lymphocytes, such as T cells and natural killer (NK) cells, have therapeutic promise in adoptive cell transfer (ACT) therapy, where the cells are activated and expanded in vitro and then infused into a patient. However, the in vitro preservation of labile lymphocytes during transfer, manipulation, and storage has been one of the bottlenecks in the development and commercialization of therapeutic lymphocytes. Herein, we suggest a cell‐in‐shell (or artificial spore) strategy to enhance the cell viability in the practical settings, while maintaining biological activities for therapeutic efficacy. A durable titanium oxide (TiO 2 ) shell is formed on individual Jurkat T cells, and the CD3 and other antigens on cell surfaces remain accessible to the antibodies. Interleukin‐2 (IL‐2) secretion is also not hampered by the shell formation. This work suggests a chemical toolbox for effectively preserving lymphocytes in vitro and developing the lymphocyte‐based cancer immunotherapy.